Three Commissioners for the Commission on Human Medicines

Announced
Body: Commission on Human Medicines
Appointing Department: Department of Health
Sector: Health
Location: London
Number of Vacancies: 3
Remuneration: Commissioners are currently remunerated at the standard rate of £325 per day.
Time Requirements: Approximately 22 days per year, including 11 meetings.

Announcement

An announcement has been made on the outcome of this appointment.

Commission on Human Medicines (CHM) – Commissioners
Professor Jamie Coleman and Ms Susan Bradford have been appointed as Commissioners of the Commission for Human Medicines for 4 years from 1 September 2018.
The appointments will involve a time commitment of approximately 22 days per year, including 11 meetings. Remuneration for the roles will be at a standard rate of £325 for the preparation required and attendance at each Commission on Human Medicines meeting.
These appointments are made in accordance with the Cabinet Office Code of Governance for Public Appointments. The regulation of public appointments against the requirements of this Code is carried out by the Commissioner for Public Appointments.
The appointments are made on merit and political activity played no part in the decision process. However, in accordance with the Code, there is a requirement for appointees’ political activity (if any declared) to be made public. Professor Coleman and Ms Bradford have not declared any political activity.

Date: 06/07/2018

View Announcement

Campaign Timeline

  • Competition Launched

    26/01/2018

  • Closed for Applications

    09/03/2018

  • Panel Sift

    28/03/2018

  • Final Interview Date

    11/05/2018

  • Announcement

    06/07/2018 at 12:00

 

Assessment Panel

Vacancy Description

The Secretary of State for Health and Social Care is looking to appoint one lay and two specialist Commissioners to the Commission on Human Medicines (CHM). CHM is an Advisory Non-Departmental Public Body, set up in law to advise UK Health Ministers on the safety, quality and efficacy of medicines for human use and on the adverse drug reactions of marketed products.

As a Commissioner of the CHM you will be required to possess or develop a working knowledge and understanding of the UK/European medicines regulatory procedures. Commissioners consider, comment and contribute by drawing on their individual expertise and judgement, on all agenda items and assist the CHM to frame clear and unequivocal advice to Ministers.

We are looking for skilled communicators with the ability to operate effectively on a national expert scientific committee. The ability to assimilate complex scientific information at short notice and being prepared to contribute actively to the work of the CHM is essential.

The two specialist post applicants will need to be recognised by their peers and/or be Fellows of the relevant Royal Colleges and be either a Cardiologist or Pharmaco-toxicologist. An interest in pharmacogenomics/ pharmacogenetics would be an advantage.

Person Specification

Role and Responsibilities of the Commissioner

Commissioners are required to:

  • possess or develop a working knowledge and understanding of the UK/European medicines regulatory procedures
  • attend all scheduled and unscheduled meetings of the CHM (and to be present for the whole meeting)
  • consider, comment and contribute by drawing on their individual expertise and judgement, as appropriate, on all agenda items and to assist the CHM to frame clear and unequivocal advice to Ministers in accordance with the CHM’s terms of reference
  • be able and prepared to speak on a range of relevant issues and not just on their own areas of specialism
  • provide formal and informal advice to Ministers between meetings when required
  • provide advice relating to applications in the European Procedures and occasionally to attend the European Medicines Agency as part of the UK delegation as necessary
  • contribute to and ensure the CHM’s advice takes account of a wider view of risk and benefit, particularly as it is perceived by patients, carers and other members of the public

Qualities required for the role of a Commissioner

To be considered, you must be able to demonstrate that you have the qualities, skills and experience to meet all the essential criteria for appointment.

Essential Criteria

  • ability to operate effectively on a national expert scientific committee
  • be skilled communicators
  • ability to assimilate complex scientific information at short notice
  • ability and prepared to contribute actively to the work of the CHM

In addition, for the two specialist posts successful candidates should also be:

  • recognised by their peers and/or be Fellows of the relevant Royal Colleges
  • be either a Cardiologist or Pharmaco-toxicologist. An interest in pharmacogenomics/pharmacogenetics would be an advantage

Additional Information

Background on some aspects of the CHM’s work

The secretariat to the CHM produces an Annual Report at the end of each calendar year which is laid before Parliament and made public.

A link to the 2016 report is available through the Gov.UK website: –

https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/634153/WEB_Statutory_CHM___BPC_Annual_Report_2016.pdf

How to Apply

The Department of Health and Social Care Appointments and Honours Team is managing this recruitment campaign on behalf of Medicines and Healthcare Products Regulatory Agency (MHRA). To make an application please email your CV, a supporting letter and completed monitoring forms to:

appointments.team@dh.gsi.gov.uk – please quote ref: A17-42 in the subject field.

If you are unable to apply by email you may send your application by post to:

Julia Peters, Department of Health and Social Care, Room 1N09, Quarry House, Quarry Hill, Leeds, LS2 7UE

Applications must be received by midday on 9nd March 2018.

The Department of Health and Social Care and MHRA promote diversity and encourage applications from all sections of the community.

Attachments
Monitoring form
GUARANTEED INTERVIEW SCHEME
Information pack final closing 9.3.18
Return to Search